CClinicalTrials.gg
WithdrawnNCT02426424Updated Apr 19, 2018

Effect Of Early C-PAP Treatment For Sleep Apnea On Rehabilitation Of Stroke Patients

A Phase 4 interventional study of Watchpat and CPAP in Sleep Apnea and Stroke, sponsored by Soroka University Medical Center. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-19.

Sponsored by Soroka University Medical Center · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Failure to have funding to perform the trial
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective randomized open label trial with control-to-treatment cross-over. The investigators wish to assess the effectiveness and safety of immediate detection and treatment for Sleep Apnea in Stroke patients. The investigators hypothesize that in patients with acute ischemic stroke a sleep apnea treatment by CPAP will result in a better neurological outcome and more successful rehabilitation.

The study will enroll 140 subjects which will be randomized into one of two arms:

  • Investigational - The sleep study will be performed during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge.
  • Control group -Will receive standard medical care. Patients will undergo sleep study at 3 months following discharge and patients diagnosed with sleep apnea will be treated with C-PAP.
Read the detailed description

Patients eligible to be enrolled in this study are patients admitted to the Department of Neurology due to acute ischemic stroke up to 72 hours from the start of the stroke symptoms.

After receiving written informed consent from the patient, patients will be randomized into the intervention and control groups (1:1). The intervention group will be tested for sleep apnea and C-PAP treatment will be initiated during the initial hospitalization. The control group will receive standard medical care. Control group patients will undergo sleep study at 3 months following discharge and patients diagnosed with sleep apnea will be treated with C-PAP.

All subjects:

  • At the baseline, physical examination MRS and NIHSS will be performed by the neurologist.
  • Sleep testing at the baseline with mobile sleep lab device (Watch PAT)
  • Four questionnaires will be administered for all patients: Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), quality of life (SF36), depression scale (Beck).
  • Blood sample will be taken for CRP, TNF-alpha, IL-6 and IL1 beta, VEGF, HBA1C, LDL and markers of endothelial dysfunction. These blood tests will be repeated at 3 and 6 months.
  • At discharge from the Neurology Department, 3 months and 6 months all patients will undergo NIHSS assessment.
  • Patients will be referred to the Soroka stroke clinic with rehabilitation program.
  • All patients will undergo 3 brain MRI scans, at baseline hospitalization, 3 and 6 months after.

Intervention group:

  • In the intervention group, the mobile sleep lab device (Watch PAT) will be used to identify patients with sleep apnea.
  • Treatment phase: Patients with (apnea hypopnea index) AHI≥15 will receive an in-hospital treatment with CPAP and continue CPAP treatment following discharge. The CPAP parameters will be titrated during the hospital stay.

Control group:

  • Patients will receive standard medical care. At three months, patients will undergo home sleep test with Watch-PAT device.
  • Patients with (apnea hypopnea index) AHI≥15 will receive CPAP treatment with titration at home.

TRIAL PROCEDURES 1. Patients eligible to be enrolled in this study are patients admitted to the Neurology Department due to stroke up to 72 hours after the showing of stroke symptoms.

  1. At the baseline, physical examination, MRS and NIHSS will be performed by one of the Neurology Department doctors.
  1. After receiving written informed consent from the patient, patients will be divided into 2 groups. Study group will have detection and treatment in 72 hours after stroke. Control group will have detection and treatment 3 months after stroke.

STUDY AND CONTROL GROUP

  1. The patient will answer four questionnaires: Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), "quality of life" (SF36) and "depression scale" (beck).
  2. Next, the mobile sleep lab device (Watch PAT) will be placed on the patient's finger which will provide the apnea-hypopnea Index (AHI) and respiratory disturbance index (RDI).
  3. Blood samples for circulating inflammatory biomarkers and endothelial dysfunction will be performed in the morning. Four tubes of peripheral venous blood will be drawn. Every study patient will be tested for the presence of pro-inflammatory state. Specifically, the investigators will measure the presence of high sensitive C Reactive Protein (CRP) and centrifuged sera will be tested (by ultra- sensitive ELISA), for levels of circulating TNF-alpha, IL-6 and IL1 beta. Sera will also be tested for vascular endothelial growth factor (VEGF) and markers of endothelial dysfunction; P-selectin. LDL, HBA1C.
  4. At discharge from the Neurology Department, the patient will undergo NIHSS assessment.
  5. Half of patients randomly chosen will be asked to join an "early treatment" group for 6 months of C-PAP treatment. Patients from the other half will be asked for C-PAP treatment at 3 months (late intervention).
  6. All four questionnaires will be completed by all patients at the end of the follow up period.
  7. MRI scan will be done at three points: CVA admission, 3 and 6 months after.
  8. Six months after baseline hospitalization, patients from both groups will answer four questionnaires: Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), "quality of life" (SF36) and "depression scale" (beck).
02

Conditions studied

  • Sleep Apnea
  • Stroke

Keywords

  • c-PAP
03

In context

Apnea

1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.

Browse Apnea studies →

Lead sponsor

Soroka University Medical Center is the lead sponsor of 157 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients over the age of 18.
  2. Admitted to the Neurology Department due to acute ischemic stroke.
  3. Able to sign informed consent.
  4. Admission NIHSS 6-12.

Exclusion criteria

Exclusion Criteria:

  1. Stroke symptom onset more than 72 hours prior to the enrollment
  2. Transient Ischemic Attack.
  3. Chronic pulmonary disease requiring home oxygen treatment.
  4. History of C-PAP treatment
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Investigatory 1

    The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.

    Device: Watchpat · Device: CPAP

  • Experimental
    Investigatory 2

    The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.

    Device: Watchpat · Device: CPAP

Interventions

  • DeviceWatchpat

    WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.

  • DeviceCPAP

    Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.

06

What researchers measure

Primary outcomes

  1. NIHSS change from the baseline to 3 months

    Change in the NIHSS score from admission to three months

    Time frame: 3 months

Secondary outcomes

  1. NIHSS change score from admission to discharge from the Neurology Department.

    Time frame: 3 months

  2. NIHSS score change from admission to 6 months following hospitalization

    Time frame: 6 months

  3. NIHSS score change from three to six months following hospitalization

    Time frame: 6 month

  4. Prevent recurrent strokes at 6 months

    Time frame: 6 months

  5. Analyse the composite of cardiovascular events at 6 months (acute myocardial infarction, coronary revascularization, death or recurrent stroke)

    Time frame: 6 months

  6. Evaluate new MRI ischemic lesions between 3 MRI scans.

    Time frame: 6 months

  7. Change Epworth Sleepiness Scale (ESS) at 3 and 6 months from the baseline

    Time frame: 6 months

  8. Change quality of life (SF36) at 3 and 6 months from the baseline

    Time frame: 6 months

  9. Change depression scale (Beck) at 3 and 6 months from the baseline

    Time frame: 6 months

  10. Change number of severe adverse events (SAE) at 3 months

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02426424
Lead sponsor
Soroka University Medical Center
Responsible party
Gal Ifergane MD (Head of Neurology Department, Soroka University Medical Center) — Principal investigator
First posted
Apr 27, 2015
Start date
Jan 2018 (estimated)
Primary completion
Jun 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Apr 19, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion